Mite Dermatophagoides Pteronyssinus
Mite Dermatophagoides Pteronyssinus Uses, Dosage, Side Effects, Food Interaction and all others data.
Mite Dermatophagoides Pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
Treatment with ACTAIR has been shown to induce a systemic antibody response towards house dust mite allergens, with an increase in specific IgG4 antibodies in some patients. These immunoglobulins may compete with IgE for allergen binding, thereby decreasing allergen capture and presentation.
| Trade Name | Mite Dermatophagoides Pteronyssinus |
| Generic | Dermatophagoides pteronyssinus |
| Dermatophagoides pteronyssinus Other Names | AE-mite, dermatophagoides pteronyssinus, Dermatophagoides pteronyssinus whole, European house dust mite, European house dust mite extract, House dust mite extract, dermatophagoides pteronyssinus, Insects (whole body), mite dermatophagoides pteronyssinus, Mite D.P., Mite D.P. (dermatophagoides pteronyssinus) standardized |
| Type | |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Mite Dermatophagoides Pteronyssinus is an extract from Mite Dermatophagoides Pteronyssinus used in allergy testing.
Mite Dermatophagoides Pteronyssinus is an allergen extract indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Mite Dermatophagoides Pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts. Mite Dermatophagoides Pteronyssinus is approved for use in adults 18 through 65 years of age.
How Mite Dermatophagoides Pteronyssinus works
The complete mechanisms of allergen immunotherapy are not clear and remain the subject of investigation. The allergic reaction is dependent on the presence of allergen-specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies sensitizes these cells, and upon interaction with the appropriate allergens, histamine and other mediators are released which produce local or systemic responses in sensitive individuals, and characteristic symptoms of atopic diseases, such as allergic rhinitis and allergic asthma. Changes in serum antibody and T-lymphocyte responses resulting from immunotherapy have been demonstrated, and these changes often correlate closely with clinical (symptom) improvements. Specific mechanisms may vary depending on the nature of the allergic disease, the allergenic specificities of patients and populations, extract formulations, route of administration, dose and duration of treatment. Subcutaneous administration of allergenic extracts is known to elicit numerous immunological changes that are both time and dose-dependent. Many of these changes appear to be related to (or a precursor to) improvements in symptoms and other clinical parameters, as noted above. Specific changes found after immunotherapy with dust mite extracts include significant increases in mite-specific IgG4 antibodies, interleukin-10-positive T cells, and several T-cell receptors, and significant decreases in serum nitric oxide, eosinophil catonic protein, interleukin-4-positive T cells and IgE-mediated basophil histamine release.
Elimination Route
Allergens in ACTAIR consist mainly of proteins and glycoproteins. There is no direct bioavailability of intact allergens in the blood. Therefore, no pharmacokinetic studies in animals or in humans have been carried out to investigate the pharmacokinetic profile and metabolism of ACTAIR.
Innovators Monograph
You find simplified version here Mite Dermatophagoides Pteronyssinus
